statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc. The United Mitochondrial Disease...

The United Mitochondrial Disease Foundation Announces Inaugural Venture Philanthropy Investment; The Mito Fund Invests $500k in Pierrepont Therapeutics, Inc.

Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on TRDA stock, giving a Buy rating on March 13. Ram Selvaraju has given h...

Entrada Therapeutics: Buy Rating on Strong Financials and Promising Clinical Pipeline

Entrada Therapeutics, Inc. (NASDAQ:TRDA  Free Report)  Investment analysts at William Blair lowered their Q1 2024 earnings per share estimates for Entrada Therapeutics in a research...

Equities Analysts Offer Predictions for Entrada Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:TRDA)

Extended Cash Runway and Progress in Duchenne Muscular Dystrophy Treatments Mark 2023 MilestonesRelated Stocks: TRDA...

Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Entrada Therapeutics expects cash to fund requirements through 2Q26

Entrada Therapeutics reports Q4 EPS (29c), consensus (17c)

Cash runway extended through the second quarter of 2026 $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 Completed dosing for third cohort of Phase 1...

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Recap: Entrada Therapeutics Q4 Earnings

Entrada Therapeutics CEO discloses sale of 1K shares...

Entrada Therapeutics CEO discloses sale of 1K shares

Entrada Therapeutics, Inc. operates as a biotechnology company. It focuses on delivery of biomolecules into the cell to treat devastating diseases. The firm offers intracellular enzyme replacement therapy and protein-protein interaction inhibitors programs. The company focuses on creating and expanding pipeline of oligonucleotide, antibody, enzyme, protein and peptide programs to target and engage underlying drivers of diseases. Entrada Therapeutics was founded by Dehua Pei in September 22, 2016 and is headquartered in Boston, MA.

Volume	28,319.00
52-Wk High	$18.44
52-Wk Low	$10.62

TRDA Entrada Therapeutics Inc

About

Feed

News

Earnings

Fundamentals